Tracked deals
3
3 tracked deals across 2020-2024.
Public Company
Healthcare
Integra LifeSciences
Princeton, New Jersey, United States
Global medical technology company dedicated to restoring lives through innovation in neurosurgery and tissue reconstruction, including specialty surgical products and devices used by healthcare professionals.
- Focus Areas
- Medical Devices, Neurosurgery, Tissue Reconstruction
- Website
- integralife.com
Recent pace
0
0 tracked deals announced in the last 12 months.
Deal mix
Buyout
3 buyout
Integra LifeSciences Acquisition Volume by Year
Last 3 years
Supporting Data
Recent Transactions
-
April 1, 2024
- Buyer
- Integra LifeSciences Holdings Corporation
- Target
- Acclarent, Inc.
- Industry
- Medical Devices
- Location
- California, United States
- Type
- Buyout
Integra LifeSciences Holdings Corporation has completed its acquisition of Acclarent, Inc., a maker of ear, nose and throat (ENT) surgical devices. The transaction expands Integra’s product portfolio into the ENT device segment, adding approximately $1 billion to the company’s total addressable market and providing scale through Acclarent’s commercial and R&D capabilities.
-
December 1, 2022
- Buyer
- Integra LifeSciences Holding Corporation
- Target
- Surgical Innovation Associates (SIA)
- Industry
- Medical Devices
- Location
- Illinois, United States
- Type
- Buyout
Integra LifeSciences agreed to acquire Surgical Innovation Associates (SIA), the developer of DuraSorb, a resorbable synthetic matrix for plastic and reconstructive (including implant-based breast) surgery. Integra will pay $50 million at closing with up to $90 million in contingent consideration to support its expansion into breast reconstruction and strengthen its soft tissue reconstruction portfolio.
-
December 16, 2020
- Buyer
- Integra LifeSciences
- Target
- ACell, Inc.
- Industry
- Medical Devices
- Location
- Maryland, United States
- Type
- Buyout
Integra LifeSciences agreed to acquire regenerative-medicine company ACell, Inc. for $300 million upfront in cash plus up to $100 million in revenue-based milestones. The acquisition adds ACell's MatriStem porcine urinary bladder matrix platform to Integra's tissue technologies portfolio and is expected to close in Q1 2021, subject to customary conditions.
Related Acquisition Pages
Selling a company? Get in front of buyers like Integra LifeSciences
Turn tracked acquisition activity into an outreach-ready buyer list.